Avammune Therapeutics: Harnessing the Power of the Innate Immune System

Avammune Therapeutics: Harnessing the Power of the Innate Immune System – The immune system is the body’s natural defense mechanism against foreign invaders, such as bacteria, viruses, and cancer cells. The immune system consists of two main branches: the adaptive immune system and the innate immune system. The adaptive immune system is the more specific and sophisticated branch, which can recognize and remember specific antigens and mount a tailored response. The innate immune system is the more general and primitive branch, which can recognize and respond to common patterns of danger signals, such as DNA, RNA, and lipids.

Avammune Therapeutics

Details of the startup:

  • CITY : Bengaluru
  • STATE : Karnataka
  • STARTED IN : 2013
  • FOUNDERS : Aditya Kulkarni and Arun Bellandur Papaiah.
  • NUMBER OF INVESTORS : 3
  • LATEST ROUND INVESTMENT : –
  • TOTAL INVESTMENT : ₹5.00M
  •   TOTAL SECURED LOANS AVAILED : ₹9.00M

You can find their website here

The innate immune system plays a crucial role in the initiation and regulation of the immune response, as well as in the direct elimination of pathogens and cancer cells. However, the innate immune system can also be dysregulated or exploited by various diseases, leading to chronic inflammation, autoimmune disorders, or immune evasion. Therefore, modulating the innate immune system can offer novel therapeutic opportunities for treating various diseases, especially cancer and infectious diseases.

That’s where Avammune Therapeutics comes in. Avammune Therapeutics is a drug discovery and development company that focuses on the modulation of the innate immune system. Avammune Therapeutics develops small molecule inhibitors of the enzymes that are involved in the generation and recognition of the innate immune signals, such as cyclic GMP-AMP synthase (cGAS) and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). Avammune Therapeutics aims to develop a pipeline of best-in-class and first-in-class drugs that can modulate the innate immune system for treating cancer and infectious diseases.

immunitoAI: The AI-Driven Solution for Novel Antibody Discovery

Features and Benefits

Avammune Therapeutics offers a unique and innovative approach to modulate the innate immune system, with the potential to address unmet medical needs and improve patient outcomes. Some of the key features and benefits of Avammune Therapeutics are:

  • Targeting the cGAS-STING Pathway: Avammune Therapeutics targets the cGAS-STING pathway, which is a key sensor and mediator of the innate immune response to cytosolic DNA. cGAS is an enzyme that catalyzes the synthesis of cyclic GMP-AMP (cGAMP), a second messenger that binds and activates STING, a transmembrane protein that triggers the production of type I interferons and other inflammatory cytokines. The cGAS-STING pathway is implicated in various diseases, such as cancer, autoimmune disorders, and viral infections. Avammune Therapeutics develops small molecule inhibitors of cGAS, which can block the production of cGAMP and the activation of STING, and thus modulate the innate immune response. Avammune Therapeutics believes that cGAS inhibitors can have multiple therapeutic applications, such as:
    • Combination Therapy for Cancer: cGAS inhibitors can be used in combination with other immuno-oncology agents, such as checkpoint inhibitors, to enhance the anti-tumor immune response and overcome the resistance mechanisms. cGAS inhibitors can also be used in combination with other cancer therapies, such as chemotherapy, radiotherapy, or oncolytic viruses, to reduce the toxicity and inflammation caused by the release of cytosolic DNA.
    • Monotherapy for Autoimmune Disorders: cGAS inhibitors can be used as monotherapy for autoimmune disorders, such as systemic lupus erythematosus (SLE), Aicardi-Goutières syndrome (AGS), or Sjögren’s syndrome, which are characterized by the accumulation of cytosolic DNA and the activation of the cGAS-STING pathway. cGAS inhibitors can suppress the production of type I interferons and other inflammatory cytokines, and thus reduce the symptoms and severity of the disease.
    • Monotherapy for Viral Infections: cGAS inhibitors can be used as monotherapy for viral infections, such as COVID-19, influenza, or herpes, which are characterized by the presence of viral DNA or RNA in the cytosol and the activation of the cGAS-STING pathway. cGAS inhibitors can inhibit the production of type I interferons and other inflammatory cytokines, and thus reduce the viral replication and the cytokine storm.
  • Targeting the ENPP1 Pathway: Avammune Therapeutics targets the ENPP1 pathway, which is a key regulator of the innate immune response to extracellular ATP. ENPP1 is an enzyme that hydrolyzes extracellular ATP, a danger signal that activates the purinergic receptors, such as P2X7, and triggers the inflammasome activation and the release of IL-1β and IL-18. The ENPP1 pathway is implicated in various diseases, such as cancer, inflammation, and metabolic disorders. Avammune Therapeutics develops small molecule inhibitors of ENPP1, which can increase the levels of extracellular ATP and the activation of the purinergic receptors, and thus modulate the innate immune response. Avammune Therapeutics believes that ENPP1 inhibitors can have multiple therapeutic applications, such as:
    • Monotherapy for Cancer: ENPP1 inhibitors can be used as monotherapy for cancer, especially for tumors that express low levels of extracellular ATP and high levels of ENPP1, such as pancreatic cancer, colorectal cancer, or ovarian cancer. ENPP1 inhibitors can increase the levels of extracellular ATP and the activation of the purinergic receptors, and thus induce the apoptosis of cancer cells and the recruitment of immune cells.
    • Combination Therapy for Cancer: ENPP1 inhibitors can be used in combination with other immuno-oncology agents, such as checkpoint inhibitors, to enhance the anti-tumor immune response and overcome the resistance mechanisms. ENPP1 inhibitors can also be used in combination with other cancer therapies, such as chemotherapy, radiotherapy, or oncolytic viruses, to increase the release of extracellular ATP and the activation of the purinergic receptors.
    • Monotherapy for Inflammation: ENPP1 inhibitors can be used as monotherapy for inflammation, such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease, which are characterized by the overproduction of IL-1β and IL-18 and the activation of the inflammasome. ENPP1 inhibitors can increase the levels of extracellular ATP and the activation of the purinergic receptors, and thus inhibit the inflammasome activation and the release of IL-1β and IL-18.
Ahammune Biosciences: A Biotech Startup with a Mission to Cure Vitiligo

Success Stories and Recognition

Avammune Therapeutics has successfully and responsibly advanced its drug discovery and development programs, with the support of various partners and investors. Some of these are:

  • Partnerships: Avammune Therapeutics has established strategic partnerships with various academic, research, and government institutions, such as IISc, IIT, NIMHANS, CSIR, and more. Avammune Therapeutics has also established collaborations with various pharmaceutical, biotechnology, and healthcare companies, such as Sun Pharma, Biocon, Dr. Reddy’s, and more. Avammune Therapeutics leverages the expertise and resources of its partners to accelerate its drug discovery and development process, and to enhance the efficacy and safety of its drugs.
  • Investments: Avammune Therapeutics has raised over $10 million in funding from various investors, such as Aten Porus Lifesciences, Oraxion Therapeutics, Avaliv Therapeutics, and more. Avammune Therapeutics uses the funding to support its research and development activities, as well as its operational and regulatory needs. Avammune Therapeutics also plans to raise more funding in the future, to advance its pipeline of drugs to the clinical stage and beyond.

 

Seagull BioSolutions: A Pioneer in Biotechnology for Healthcare

Avammune Therapeutics is a company that develops small molecule inhibitors of the innate immune system for treating cancer and infectious diseases. Avammune Therapeutics targets the cGAS-STING pathway and the ENPP1 pathway, which are key sensors and mediators of the innate immune response. Avammune Therapeutics aims to develop a pipeline of best-in-class and first-in-class drugs that can modulate the innate immune system for treating various diseases.

Avammune Therapeutics is one of the global elite in the field of innate immunity modulation, and South Asia’s first company in this domain. Avammune Therapeutics has successfully and responsibly advanced its drug discovery and development programs, with the support of various partners and investors. Avammune Therapeutics has also received several awards and recognition for its innovation and impact.

If you are interested in learning more about Avammune Therapeutics and its products and services, you can visit their website or follow them on social media. You can also contact them at info@avammune.com or call them at +49-1525846-5301. Avammune Therapeutics is always looking for partners, distributors, and customers who share their vision and mission of harnessing the power of the innate immune system.

You May Also Like

More From Author

+ There are no comments

Add yours